Cargando…

The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer

Prostate cancer (PCa) is one of the most common types of malignant tumor, which places a major burden on the health of men, worldwide. A prerequisite to ensure good treatment outcomes for patients with PCa is an accurate diagnosis. The present study aimed to investigate the diagnostic value of prost...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Daijun, Shi, Xiang, Lei, Yu, Zhou, Xianrong, Chen, Qiuxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377033/
https://www.ncbi.nlm.nih.gov/pubmed/32724384
http://dx.doi.org/10.3892/ol.2020.11658
_version_ 1783562143807832064
author Yang, Daijun
Shi, Xiang
Lei, Yu
Zhou, Xianrong
Chen, Qiuxiang
author_facet Yang, Daijun
Shi, Xiang
Lei, Yu
Zhou, Xianrong
Chen, Qiuxiang
author_sort Yang, Daijun
collection PubMed
description Prostate cancer (PCa) is one of the most common types of malignant tumor, which places a major burden on the health of men, worldwide. A prerequisite to ensure good treatment outcomes for patients with PCa is an accurate diagnosis. The present study aimed to investigate the diagnostic value of prostate-specific antigen (PSA) and α-methylacyl-CoA racemase (P504S) in PCa, using the tumor-associated immunolabels. In total, clinical data was collected from 125 patients undergoing prostate biopsy or surgery between January 2015 and September 2019, and stratified into: PCa (45), benign prostatic hyperplasia (BPH) (60) and unconfirmed diagnosis (20). Immunohistochemistry analysis was performed to assess PSA and P504S expression levels in each group compared with that in the controls (the normal tissue in each group was the internal control). The results demonstrated that the expression level of P504S was significantly higher in the PCa group compared with that in the BPH group. Furthermore, no significant association was observed in the PCa group between PSA and P504S expression levels, and the Gleason grading groups. A total of 20 unconfirmed diagnoses was verified via PSA/P504S. Taken together, the results suggest that combination PSA and P504S have a positive effect in identifying prostate cancer. However, PSA and P504S still have limitations in their diagnosis and the final results need to be carefully and comprehensively analyzed, thus further studies are required to determine their diagnostic values.
format Online
Article
Text
id pubmed-7377033
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-73770332020-07-27 The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer Yang, Daijun Shi, Xiang Lei, Yu Zhou, Xianrong Chen, Qiuxiang Oncol Lett Articles Prostate cancer (PCa) is one of the most common types of malignant tumor, which places a major burden on the health of men, worldwide. A prerequisite to ensure good treatment outcomes for patients with PCa is an accurate diagnosis. The present study aimed to investigate the diagnostic value of prostate-specific antigen (PSA) and α-methylacyl-CoA racemase (P504S) in PCa, using the tumor-associated immunolabels. In total, clinical data was collected from 125 patients undergoing prostate biopsy or surgery between January 2015 and September 2019, and stratified into: PCa (45), benign prostatic hyperplasia (BPH) (60) and unconfirmed diagnosis (20). Immunohistochemistry analysis was performed to assess PSA and P504S expression levels in each group compared with that in the controls (the normal tissue in each group was the internal control). The results demonstrated that the expression level of P504S was significantly higher in the PCa group compared with that in the BPH group. Furthermore, no significant association was observed in the PCa group between PSA and P504S expression levels, and the Gleason grading groups. A total of 20 unconfirmed diagnoses was verified via PSA/P504S. Taken together, the results suggest that combination PSA and P504S have a positive effect in identifying prostate cancer. However, PSA and P504S still have limitations in their diagnosis and the final results need to be carefully and comprehensively analyzed, thus further studies are required to determine their diagnostic values. D.A. Spandidos 2020-08 2020-05-21 /pmc/articles/PMC7377033/ /pubmed/32724384 http://dx.doi.org/10.3892/ol.2020.11658 Text en Copyright: © Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Yang, Daijun
Shi, Xiang
Lei, Yu
Zhou, Xianrong
Chen, Qiuxiang
The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer
title The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer
title_full The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer
title_fullStr The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer
title_full_unstemmed The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer
title_short The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer
title_sort auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-coa racemase in prostate cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377033/
https://www.ncbi.nlm.nih.gov/pubmed/32724384
http://dx.doi.org/10.3892/ol.2020.11658
work_keys_str_mv AT yangdaijun theauxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT shixiang theauxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT leiyu theauxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT zhouxianrong theauxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT chenqiuxiang theauxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT yangdaijun auxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT shixiang auxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT leiyu auxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT zhouxianrong auxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer
AT chenqiuxiang auxiliarydiagnosticvalueofprostatespecificantigenandamethylacylcoaracemaseinprostatecancer